Whats Next: Regulatory filing for weight management: by end of 2025 Submission for type 2 diabetes: expected in 2026 Drug discovered by Chugai, licensed by Lilly in 2018 Implication: Orforglipron could become the first once-daily oral GLP-1 therapy with potent glucose-lowering and weight-loss benefits, potentially disrupting the injectable incretin market
Semaglutide and walking capacity in patients with peripheral artery disease and type 2 diabetes (STRIDE): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
However, the same research demonstrates that stopping the medication leads to weight regain in most people, suggesting that extended treatment better supports lasting results than short-term use alone
Rapid urbanization, changing dietary habits, and sedentary lifestyles are driving an upsurge in diabetes cases across China, India, Japan, and Southeast Asia